Investigating the pathogenesis and risk of Type 2 diabetes: Clinical applications of metabolomics

Clinical Lipidology

Volumn 7, Issue 6, 2012, Pages 641-659

  Ng, Theodore W ^a   Khan, Anmar A ^a,b   Meikle, Peter J ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

biomarker; insulin resistance; lipidomics; mass spectrometry; nuclear magnetic resonance spectroscopy; obesity; Type 2 diabetes

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETOACETIC ACID; AMINO ACID; AROMATIC AMINO ACID; BIGUANIDE; BRANCHED CHAIN AMINO ACID; CERAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; LACTIC ACID; LIPID; LIPOPROTEIN; METFORMIN; PEPTIDE DERIVATIVE; PHOSPHOLIPID; PIOGLITAZONE; PLACEBO; PYRUVIC ACID; REPAGLINIDE; ROSIGLITAZONE; SPHINGOLIPID; SULFONYLUREA; TRIACYLGLYCEROL; TRIMETHYLAMINE OXIDE; TROGLITAZONE;

ATHEROSCLEROSIS; CLINICAL EFFECTIVENESS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EARLY DIAGNOSIS; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; LIPIDOMICS; METABOLITE; METABOLOMICS; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH BYPASS; TREATMENT DURATION; TREATMENT PLANNING; WEIGHT REDUCTION;

EID: 84871396690     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.12.75     Document Type: Review

References (129)

1. Magliano DJ, Shaw JE, Shortreed SM et al. Lifetime risk and projected population prevalence of diabetes. Diabetologia 51(12), 2179-2186 (2008).
2. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 35(Suppl. 1), S64-S71 (2012).
3. Nandish S, Wyatt J, Bailon O, Smith M, Oliveros R, Chilton R. Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus. Am. J. Cardiol. 108(Suppl. 3), B42- B51 (2011).
4. Power C, Thomas C. Changes in BMI, duration of overweight and obesity, and glucose metabolism: 45 years of follow-up of a birth cohort. Diabetes Care 34(9), 1986-1991 (2011).
5. Kawakami N, Takatsuka N, Shimizu H, Ishibashi H. Effects of smoking on the incidence of non-insulin-dependent diabetes mellitus. Replication and extension in a Japanese cohort of male employees. Am. J. Epidemiol. 145(2), 103-109 (1997). (Pubitemid 27045315)
6. Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20(4), 537-544 (1997).
7. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344(18), 1343-1350 (2001). (Pubitemid 32378388)
8. The Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 35(4), 723-730 (2012).
9. Fiehn O. Combining genomics, metabolome analysis, and biochemical modelling to understand metabolic networks. Comp. Funct. Genomics 2(3), 155-168 (2001). (Pubitemid 32590962)
10. Thomas A, Lenglet S, Chaurand P et al. Mass spectrometry for the evaluation of cardiovascular disease based on proteomics and lipidomics. Thromb. Haemost. 106(1), 20-33 (2011).
11. Becker S, Kortz L, Helmschrodt C, Thiery J, Ceglarek U. LC-MS-based metabolomics in the clinical laboratory. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 883-884, 68-75 (2012).
12. Wang Z, Klipfell E, Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472(7341), 57-63 (2011).
13. Leahy JL. Pathogenesis of Type 2 diabetes mellitus. Arch. Med. Res. 36(3), 197-209 (2005). (Pubitemid 40755133)
14. D'Agostino RB Jr, Hamman RF, Karter AJ, Mykkanen L, Wagenknecht LE, Haffner SM. Cardiovascular disease risk factors predict the development of Type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care 27(9), 2234-2240 (2004). (Pubitemid 39167191)
15. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch. Int. Med. 167(10), 1068-1074 (2007). (Pubitemid 46835795)
16. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 45(1), 42-72 (2006). (Pubitemid 43170804)
17. Car H, Zendzian-Piotrowska M, Prokopiuk S et al. Ceramide profiles in the brain of rats with diabetes induced by streptozotocin. FEBS J. 279(11), 1943-1952 (2012).
18. Haus JM, Kashyap SR, Kasumov T et al. Plasma ceramides are elevated in obese subjects with Type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 58(2), 337-343 (2009).
19. De Mello VD, Lankinen M, Schwab U et al. Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 52(12), 2612-2615 (2009).
20. Hu W, Ross J, Geng T, Brice SE, Cowart LA. Differential regulation of dihydroceramide desaturase by palmitate versus monounsaturated fatty acids. J. Biol. Chem. 286(19), 16596-16605 (2011).
21. Samad F, Hester KD, Yang G, Hannun YA, Bielawski J. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 55(9), 2579-2587 (2006). (Pubitemid 44871159)
22. Shui G, Stebbins JW, Lam BD et al. Comparative plasma lipidome between human and cynomolgus monkey. are plasma polar lipids good biomarkers for diabetic monkeys? PLoS ONE 6(5), e19731 (2011).
23. Kabayama K, Sato T, Saito K et al. Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Proc. Natl Acad. Sci. USA 104(34), 13678-13683 (2007).
24. Tagami S, Inokuchi Ji J, Kabayama K et al. Ganglioside GM3 participates in the pathological conditions of insulin resistance. J. Biol. Chem. 277(5), 3085-3092 (2002). (Pubitemid 34953168)
25. Yamashita T, Hashiramoto A, Haluzik M et al. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc. Natl Acad. Sci. USA 100(6), 3445-3449 (2003). (Pubitemid 36356603)
26. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J. Cardiovasc. Risk 7(5), 325-331 (2000).
27. Younis NN, Soran H, Pemberton P, Charlton-Menys V, El-Seweidy MM, Durrington PN. Small dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetes. Clin. Sci. doi:10.1042/CS20120304 (2012) (Epub ahead of print).
28. Adiels M, Boren J, Caslake MJ et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 25(8), 1697-1703 (2005). (Pubitemid 41098943)
29. Cummings MH, Watts GF, Umpleby AM et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia 38(8), 959-967 (1995).
30. Dane-Stewart CA, Watts GF, Barrett PH et al. Chylomicron remnant metabolism studied with a new breath test in postmenopausal women with and without Type 2 diabetes mellitus. Clin. Endocrinol. 58(4), 415-420 (2003). (Pubitemid 36390612)
31. Mikhailidis DP, Elisaf M, Rizzo M et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr. Vasc. Pharmacol. 9(5), 531-532 (2011).
32. Mikhailidis DP, Elisaf M, Rizzo M et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr. Vasc. Pharmacol. 9(5), 533-571 (2011).
33. Frenais R, Ouguerram K, Maugeais C et al. High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study. Diabetologia 40(5), 578-583 (1997). (Pubitemid 27186795)
34. Duvillard L, Pont F, Florentin E, Gambert P, Verges B. Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 152(1), 229- 237 (2000).
35. Calvo C, Talussot C, Ponsin G, Berthezene F. Non enzymatic glycation of apolipoprotein A-I. Effects on its self-association and lipid binding properties. Biochem. Biophys. Res. Comm. 153(3), 1060-1067 (1988).
36. Calvo C, Ponsin G, Berthezene F. Characterization of the non enzymatic glycation of high density lipoprotein in diabetic patients. Diabetes Metab. 14(3), 264- 269 (1988).
37. Hedrick CC, Thorpe SR, Fu MX et al. Glycation impairs high-density lipoprotein function. Diabetologia 43(3), 312-320 (2000). (Pubitemid 30163474)
38. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog. Lipid Res. 51(4), 314-324 (2012).
39. Persegol L, Verges B, Foissac M, Gambert P, Duvillard L. Inability of HDL from Type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 49(6), 1380-1386 (2006).
40. Vaisar T, Pennathur S, Green PS et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117(3), 746-756 (2007). (Pubitemid 46348533)
41. McPherson PA, Young IS, Mckibben B, McEneny J. High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation. J. Lipid Res. 48(1), 86-95 (2007). (Pubitemid 46052900)
42. Stahlman M, Pham HT, Adiels M et al. Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with Type 2 diabetes. Diabetologia 55(4), 1156- 1166 (2012).
43. Rhee EP, Cheng S, Larson MG et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J. Clin. Invest. 121(4), 1402-1411 (2011).
44. Kotronen A, Velagapudi VR, Yetukuri L et al. Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia 52(4), 684-690 (2009).
45. Hiukka A, Stahlman M, Pettersson C et al. ApoCIII-enriched LDL in Type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes 58(9), 2018-2026 (2009).
46. Wang J, Stancakova A, Soininen P et al. Lipoprotein subclass profiles in individuals with varying degrees of glucose tolerance. a population-based study of 9399 Finnish men. J. Intern. Med. doi:10.1111/j.1365-2796. 2012.02562.x (2012) (Epub ahead of print).
47. Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, Type 2 diabetes mellitus, and familial combined hyperlipidemia. Am. J. Cardiol. 92(4A), J27-J33 (2003).
48. Wang TJ, Larson MG, Vasan RS et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 17(4), 448-453 (2011).
49. Newgard CB, An J, Bain JR et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 9(4), 311-326 (2009).
50. Huffman KM, Shah SH, Stevens RD et al. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 32(9), 1678-1683 (2009).
51. Suhre K, Meisinger C, Döring A et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 5(11), e13953 (2010).
52. Tai ES, Tan ML, Stevens RD et al. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia 53(4), 757-767 (2010).
53. Mihalik SJ, Michaliszyn SF, De Las Heras J et al. Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and Type 2 diabetes: evidence for enhanced mitochondrial oxidation. Diabetes Care 35(3), 605-611 (2012).
54. Shah SH, Bain JR, Muehlbauer MJ et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events/clinical perspective. Circ. Cardiovasc. Genet. 3(2), 207-214 (2010).
55. Park JH, Lee SY. Fermentative production of branched chain amino acids: a focus on metabolic engineering. Appl. Microbiol. Biotechnol. 85(3), 491-506 (2010).
56. Gall WE, Beebe K, Lawton KA et al. a-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE 5(5), e10883 (2010).
57. Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 15(5), 606-614 (2012).
58. Laferrere B, Reilly D, Arias S et al. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci.Transl Med. 3(80), 80re82 (2011).
59. Ashcroft FM, Rorsman P. Diabetes mellitus and the beta cell: the last ten years. Cell 148(6), 1160-1171 (2012).
60. Angelakopoulou A, Shah T, Sofat R et al. Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration. Eur. Heart J. 33(3), 393-407 (2012).
61. Demirkan A, Van Duijn CM, Ugocsai P et al. Genome-wide association study identifies novel loci associated with circulating phospho- and sphingolipid concentrations. PLoS Genet. 8(2), e1002490 (2012).
62. Kettunen J, Tukiainen T, Sarin AP et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat. Genet. 44(3), 269-276 (2012).
63. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 26(9), 2653-2664 (2003). (Pubitemid 37055447)
64. Wright AD, Dodson PM. Diabetic retinopathy and blockade of the renin- angiotensin system: new data from the DIRECT study programme. Eye (Lond.) 24(1), 1-6 (2010).
65. Li X, Luo X, Lu X, Duan J, Xu G. Metabolomics study of diabetic retinopathy using gas chromatography-mass spectrometry: a comparison of stages and subtypes diagnosed by western and Chinese medicine. Mol. Biosys. 7(7), 2228-2237 (2011).
66. Schwartzman ML, Iserovich P, Gotlinger K et al. Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy. Diabetes 59(7), 1780-1788 (2010).
67. Kawasaki A, Han MH, Wei JY, Hirata K, Otori Y, Barnstable CJ. Protective effect of arachidonic acid on glutamate neurotoxicity in rat retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 43(6), 1835-1842 (2002). (Pubitemid 34587029)
68. Collins AJ, Foley RN, Herzog C et al. Excerpts from the US Renal Data System 2009 Annual Data Report. Am. J. Kidney Dis. 55(1 Suppl. 1), S1-S420, A426-A427 (2010).
69. Han L-D, Xia J-F, Liang Q-L et al. Plasma esterified and non-esterified fatty acids metabolic profiling using gas chromatography-mass spectrometry and its application in the study of diabetic mellitus and diabetic nephropathy. Anal. Chim. Acta 689(1), 85-91 (2011).
70. Zhu C, Liang Q-L, Hu P, Wang Y-M, Luo G-A. Phospholipidomic identification of potential plasma biomarkers associated with Type 2 diabetes mellitus and diabetic nephropathy. Talanta 85(4), 1711-1720 (2011).
71. Liu G, Han F, Yang Y et al. Evaluation of sphingolipid metabolism in renal cortex of rats with streptozotocin-induced diabetes and the effects of rapamycin. Nephrol. Dial. Transplant. 26(5), 1493-1502 (2011).
72. Ng D, Salim A, Liu Y et al. A metabolomic study of low estimated GFR in non-proteinuric Type 2 diabetes mellitus. Diabetologia 55(2), 499-508 (2012).
73. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States. Centers for Disease Control and Prevention, GA, USA (2011).
74. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol. Therapeut. 120(1), 1-34 (2008).
75. Patti GJ, Yanes O, Shriver LP et al. Metabolomics implicates altered sphingolipids in chronic pain of neuropathic origin. Nat. Chem. Biol. 8(3), 232-234 (2012).
76. Hur J, Sullivan KA, Pande M et al. The identification of gene expression profiles associated with progression of human diabetic neuropathy. Brain 134(Pt 11), 3222-3235 (2011).
77. Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin. Chem. 58(1), 139-147 (2012).
78. Ekroos K, Janis M, Tarasov K, Hurme R, Laaksonen R. Lipidomics: a tool for studies of atherosclerosis. Curr. Atheroscler. Rep. 12(4), 273-281 (2010).
79. Waterman CL, Kian-Kai C, Griffin JL. Metabolomic strategies to study lipotoxicity in cardiovascular disease. Biochim. Biophys. Acta. 1801(3), 230-234 (2010).
80. Rasmiena AA, Ng TW, Meikle PJ. Metabolomics and ischaemic heart disease. Clin. Sci. (2012) (In Press).
81. Heianza Y, Arase Y, Fujihara K et al. Screening for pre-diabetes to predict future diabetes using various cut-off points for HbA1c and impaired fasting glucose: the Toranomon Hospital Health Management Center Study 4 (TOPICS 4). Diabetic Med. 29(9), e279-e285 (2012).
82. Cox ME, Edelman D. Tests for screening and diagnosis of Type 2 diabetes. Clin. Diabetes 27(4), 132-138 (2009).
83. American Diabetes Association. Executive summary: standards of medical care in diabetes - 2012. Diabetes Care 35(Suppl. 1), S4-S10 (2012).
84. Nomura K, Inoue K, Akimoto K. A two-step screening, measurement of HbA1c in association with FPG, may be useful in predicting diabetes. PLoS ONE 7(4), e36309 (2012).
85. Katsiki N, Papanas N, Mikhailidis DP, Fonseca VA. Glycated hemoglobin A(1)c (HbA(1)c) and diabetes: a new era? Curr. Med. Res. Opin. 27(Suppl. 3), 7-11 (2011).
86. Kitabchi AE, Temprosa M, Knowler WC et al. Role of insulin secretion and sensitivity in the evolution of Type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 54(8), 2404-2414 (2005). (Pubitemid 41134269)
87. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346(6), 393-403 (2002). (Pubitemid 34437694)
88. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack Jr. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med. J. Aust. 186(9), 461-465 (2007). (Pubitemid 46806823)
89. Shaw JE, Zimmet PZ, De Courten M et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 22(3), 399-402 (1999). (Pubitemid 29106893)
90. Soderberg S, Zimmet P, Tuomilehto J et al. High incidence of Type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius. J. Intern. Med. 256(1), 37-47 (2004). (Pubitemid 38813618)
91. Chen L, Magliano DJ, Balkau B et al. AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures. Med. J. Aust. 192(4), 197-202 (2010).
92. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict Type 2 diabetes risk. Diabetes Care 26(3), 725-731 (2003). (Pubitemid 36929335)
93. Hanley AJ, Williams K, Gonzalez C et al. Prediction of Type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study. Diabetes 52(2), 463-469 (2003). (Pubitemid 36173204)
94. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for Type 2 diabetes: systematic review. BMJ 343, d7163 (2011).
95. Chen L, Magliano DJ, Balkau B et al. Maximizing efficiency and cost-effectiveness of Type 2 diabetes screening: the AusDiab study. Diabet. Med. 28(4), 414-423 (2011).
96. Yang J, Xu G, Hong Q et al. Discrimination of Type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profiles. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 813(1-2), 53-58 (2004). (Pubitemid 39535428)
97. Wang C, Kong H, Guan Y et al. Plasma phospholipid metabolic profiling and biomarkers of Type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Anal. Chem. 77(13), 4108-4116 (2005). (Pubitemid 40934277)
98. Meikle PJ, Wong G, Tsorotes D et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 31(11), 2723-2732 (2011).
99. Wurtz P, Makinen VP, Soininen P et al. Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes 61(6), 1372-1380 (2012).
100. Floegel A, Stefan N, Yu Z et al. Identification of serum metabolites associated with risk of Type 2 diabetes using a targeted metabolomic approach. Diabetes doi:10.2337/db12-0495 (2012) (Epub ahead of print).
101. Kaddurah-Daouk R, Baillie RA, Zhu H et al. Lipidomic analysis of variation in response to simvastatin in the cholesterol and pharmacogenetics study. Metabolomics 6(2), 191-201 (2010).
102. Salem NA, Assaf N, Ahmed HH. Pleiotropic effects of rimonabant and simvastatin on obesity associated multiple metabolic risk factors in rats. Eur. Rev. Med. Pharmacol. Sci. 16(6), 797-807 (2012).
103. Kirpichnikov D, Mcfarlane SI, Sowers Jr. Metformin: an update. Ann. Intern. Med. 137(1), 25-33 (2002). (Pubitemid 34705373)
104. Huo T, Cai S, Lu X, Sha Y, Yu M, Li F. Metabonomic study of biochemical changes in the serum of Type 2 diabetes mellitus patients after the treatment of metformin hydrochloride. J. Pharm. Biomed. Anal. 49(4), 976-982 (2009).
105. Watkins SM, Reifsnyder PR, Pan HJ, German JB, Leiter EH. Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J. Lipid. Res. 43(11), 1809-1817 (2002). (Pubitemid 35315798)
106. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356(24), 2457-2471 (2007). (Pubitemid 46919772)
107. Viberti G, Kahn SE, Greene DA et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed Type 2 diabetes. Diabetes Care 25(10), 1737-1743 (2002). (Pubitemid 41071079)
108. Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368(9541), 1096-1105 (2006).
109. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373(9681), 2125-2135 (2009).
110. Van Doorn M, Vogels J, Tas A et al. Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. Br. J. Clin. Pharmacol. 63(5), 562- 574 (2007). (Pubitemid 46632578)
111. Qiu Y, Rajagopalan D, Connor SC et al. Multivariate classification analysis of metabolomic data for candidate biomarker discovery in Type 2 diabetes mellitus. Metabolomics 4, 337-346 (2008).
112. Bao Y, Zhao T, Wang X, Qiu Y, Su M, Jia W. Metabonomic variations in the drug-treated Type 2 diabetes mellitus patients and healthy volunteers. J. Proteome Res. 8(4), 1623-1630 (2009).
113. Pantalone KM, Kattan MW, Yu C et al. Increase in overall mortality risk in patients with Type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes. Metab. 14(9), 803-809 (2012).
114. Barnett AH. The role of GLP-1 mimetics and basal insulin analogues in Type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes. Metab. 14(4), 304-314 (2012).
115. Kawamori R, Inagaki N, Araki E et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with Type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes. Metab. 14(4), 348-357 (2012).
116. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in Type 2 diabetes mellitus. Mol. Cell. Endocrinol. 297(1-2), 127-136 (2009).
117. Ng TW, Watts GF, Barrett PH, Rye KA, Chan DC. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care 30(11), 2945-2950 (2007). (Pubitemid 350083149)
118. Noakes M, Clifton PM. Changes in plasma lipids and other cardiovascular risk factors during 3 energy-restricted diets differing in total fat and fatty acid composition. Am. J. Clin. Nutr. 71(3), 706-712 (2000). (Pubitemid 30118562)
119. Riches FM, Watts GF, Hua J, Stewart GR, Naoumova RP, Barrett PH. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J. Clin. Endocrinol. Metab. 84(8), 2854-2861 (1999). (Pubitemid 30642022)
120. Schwab U, Seppanen-Laakso T, Yetukuri L et al. Triacylglycerol fatty acid composition in diet-induced weight loss in subjects with abnormal glucose metabolism - the GENOBIN study. PLoS ONE 3(7), e2630 (2008).
121. Renner S, Romisch-Margl W, Prehn C et al. Changing metabolic signatures of amino acids and lipids during the prediabetic period in a pig model with impaired incretin function and reduced beta-cell mass. Diabetes 61(8), 2166-2175 (2012).
122. Zeng M, Liang Y, Li H et al. Plasma metabolic fingerprinting of childhood obesity by GC/MS in conjunction with multivariate statistical analysis. J. Pharm. Biomed. Anal. 52(2), 265-272 (2010).
123. Shah SH, Crosslin DR, Haynes CS et al. Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia 55(2), 321-330 (2012).
124. Mutch DM, Fuhrmann JC, Rein D et al. Metabolite profiling identifies candidate markers reflecting the clinical adaptations associated with Roux-en-Y gastric bypass surgery. PLoS ONE 4(11), e7905 (2009).
125. Pietilainen KH, Sysi-Aho M, Rissanen A et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects - a monozygotic twin study. PLoS ONE 2(2), (2007).
126. WHO. Diabetes Fact Sheet No 312. September 2012. www.who.int/mediacentre/ factsheets/fs312/en/index.html
127. WHO. Use of Glycated Haemoglobin (HbA1C) in the Diagnosis of Diabetes Mellitus 2011. www.who.int/diabetes/publications/diagnosis-diabetes2011/en/ index.html
128. Australian Institute of Health and Welfare. The Latest Statistics on Diabetes in Australia 2012. www.aihw.gov.au/diabetes
129. IMS Institute for Healthcare Informatics. The Use of Medicines in the USA: Review of 2010. www.imshealth.com/imshealth/Global/Content/IMS%20Institute/ Documents/IHII-UseOfMed-report%20.pdf